Pfizer Gets CML Drug Rejection From UK BodyPfizer Gets CML Drug Rejection From UK Body
Pfizer's new chronic myeloid leukemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
EUTOS Score Validated for Predicting Treatment Outcomes With TKI Therapy
A new study validates a simple prognostic score, the EUTOS score, as a useful tool in predicting the therapeutic effects of TKIs for chronic myeloid leukemia. (Source: Cancer Network)
Source: Cancer Network - July 12, 2013 Category: Cancer & Oncology Source Type: news
Ponatinib Receives Marketing Authorization in Europe for CML and Ph+ ALL
ARIAD has received marketing authorization from the European Commission for ponatinib (Iclusig) in chronic myeloid leukemia and acute lymphoblastic leukemia. (Source: Cancer Network)
Source: Cancer Network - July 12, 2013 Category: Cancer & Oncology Source Type: news
Europe Approves Ponatinib as Orphan Drug for LeukemiasEurope Approves Ponatinib as Orphan Drug for Leukemias
Ponatinib offers hope to some patients with chronic myeloid leukemia or acute lymphoblastic leukemia who have stopped responding to other therapies. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Updates Dasatinib Label for Chronic Myeloid LeukemiaFDA Updates Dasatinib Label for Chronic Myeloid Leukemia
There are new safety and efficacy data for patients with Philadelphia-chromosome-positive chronic myeloid leukemia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Complex genetic architectures: Some common symptoms of trisomy 21
(Université de Genève) In a study conducted by Professor Stylianos Antonarakis' group from the Faculty of Medicine of the University of Geneva, researchers have identified the genomic variations associated with trisomy 21, determining the risk of congenital heart disease in people with Down syndrome. These result add to other research conducted by the same team about chronic myeloid leukemia, a severe form of leukemia that often affects people with Down syndrome. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2013 Category: Global & Universal Source Type: news
TKI Therapy Affects Quality of Life in CML PatientsTKI Therapy Affects Quality of Life in CML Patients
Patients with chronic myeloid leukemia (CML) being treated with tyrosine kinase inhibitors (TKIs) experience symptoms that can adversely affect their quality of life. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Intermittent Imatinib for Elderly CML Patients Shows Promise
A phase II study found that an alternative imatinib treatment schedule for elderly patients with chronic myeloid leukemia (CML) could be an effective way to reduce dosing requirements of the drug. (Source: Cancer Network)
Source: Cancer Network - June 15, 2013 Category: Cancer & Oncology Source Type: news
Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news
Chronic Myeloid Leukemia Patients On Kinase Inhibitors Report Serious Quality-Of-Life Issues
Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance. The researchers say it is important to improve the patients' quality of life because most will take tyrosine kinase inhibitors for the rest of their lives. Their study appeared in a recent issue of Supportive Care in Cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Quality-of-life issues need to be addressed for CML patients, Moffitt researchers say
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance. The researchers say it is important to improve the patients' quality of life because most will take tyrosine kinase inhibitors for the rest of their lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2013 Category: Global & Universal Source Type: news
New Drug Target Identified In Deadly Form Of Leukemia
A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia (CML), making it possible to develop drugs that may extend the survival of these patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Targeted cancer therapy pioneers tapped to receive the 2013 $100,000 Taubman Prize
(University of Michigan Health System) Two physician-scientists whose research transformed chronic myeloid leukemia from a routinely fatal to a manageable condition will share the 2013 Taubman Prize for Excellence in Translational Medical Science. The $100,000 prize is given by the A. Alfred Taubman Medical Research Institute, based at the University of Michigan Medical School. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2013 Category: Global & Universal Source Type: news
Singapore research team identifies new drug target in deadly form of leukemia
(Duke University Medical Center) Researchers at the Duke-NUS Graduate Medical School in Singapore have identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, giving new hope to future treatments for this deadly form of cancer.
(Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2013 Category: Global & Universal Source Type: news
Woman with leukemia meets researchers of her life-saving drug
ALBANY, N.Y., May 16 (UPI) -- A 26-year-old U.S. woman diagnosed with chronic myelogenous leukemia in 2010 says she might not be alive if not for $200,000 in free cancer medication. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 17, 2013 Category: Consumer Health News Source Type: news
